- Tesaro (TSRO) has signed a global licensing deal with privately held AnaptysBio for a portfolio of antibodies that could be used to develop cancer immunotherapies.
- Tesaro will pay AnaptysBio $17M up front and development costs. For each development project, Tesaro will pay $18M in R&D milestones and $90M related to regulatory progress. AnaptysBio will also receive royalties on any product sales. (PR)
at CNBC.com (May 12, 2014)